Going Up: What's Behind the Growth in IVIG Demand
bstquarterly.com · 2,443 words · saved by 1 readers
N/A
“There is still much to be learned about immunoglobulin therapy, and many more clinical applications may yet emerge.”1 — Stephen Jolles, University Hospital of Wales — Srini Kaveri, French Institute of Health and Medical Research — Jordan Orange, University of Pennsylvania School of Medicine By Keith Berman, MPH, MBA LAUNCHED IN EUROPE in the late 1970s and here in the plasma-based therapeutics. Twenty-five years later, 2015 sales of U.S. in 1981, the first intravenous immune globulin (IVIG)…
saved by
related reading
- Intravenous Immunoglobulin (IVIG) - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov
- Why we didn't get a malaria vaccine sooner - Works in Progress Magazineworksinprogress.co
- Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment - PMCncbi.nlm.nih.gov
- Cure all diseasesworksinprogress.news
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Progress Deferred: mRNA Vaccine Development Lessons | IFPifp.org
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- Medicine's Endgamenotboring.co
- Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR - PMCncbi.nlm.nih.gov
- Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children - PubMedpubmed.ncbi.nlm.nih.gov
- Current progress in innovative engineered antibodies | Protein & Cell | Springer Nature Linklink.springer.com
- Phage Display Derived Monoclonal Antibodies: From Bench to Bedsidencbi.nlm.nih.gov